Advertisement
UK markets open in 2 hours 30 minutes
  • NIKKEI 225

    38,384.54
    +832.38 (+2.22%)
     
  • HANG SENG

    17,110.21
    +281.28 (+1.67%)
     
  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,340.20
    -1.90 (-0.08%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,580.50
    +245.10 (+0.46%)
     
  • CMC Crypto 200

    1,436.27
    +21.51 (+1.52%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Independent Director Robert Webb Just Bought 1.6% More Shares In National Health Investors, Inc. (NYSE:NHI)

Even if it's not a huge purchase, we think it was good to see that Robert Webb, the Independent Director of National Health Investors, Inc. (NYSE:NHI) recently shelled out US$88k to buy stock, at US$58.50 per share. However, it only increased their shares held by 1.6%, and it wasn't a huge purchase by absolute value, either.

View our latest analysis for National Health Investors

The Last 12 Months Of Insider Transactions At National Health Investors

Over the last year, we can see that the biggest insider purchase was by Independent Director Robert Adams for US$332k worth of shares, at about US$66.45 per share. That means that even when the share price was higher than US$58.40 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

ADVERTISEMENT

National Health Investors insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

National Health Investors is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of National Health Investors

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that National Health Investors insiders own 4.0% of the company, worth about US$109m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

What Might The Insider Transactions At National Health Investors Tell Us?

It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. When combined with notable insider ownership, these factors suggest National Health Investors insiders are well aligned, and quite possibly think the share price is too low. Nice! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 3 warning signs for National Health Investors you should be aware of, and 1 of these shouldn't be ignored.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.